Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.33 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.32 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12535907 | 0.89 | CYP1A2 (0.37) | CYP1A2MAPK1PLA2G1BPLA2G2ACA12 | |
| SCHEMBL9289906 | 0.86 | CYP1A2 (0.44) | CYP1A2MAPK1PLA2G1BPLA2G2ACA12 | |
| SCHEMBL20076527 | 0.86 | CYP1A2 (0.39) | CYP1A2MAPK1PLA2G1BPLA2G2ACA12 | |
| SCHEMBL35704 | 0.84 | CYP1A2 (0.46) | CYP1A2MAPK1PLA2G1BPLA2G2ACA12 | |
| SCHEMBL806005 | 0.84 | — | — | |
| SCHEMBL20145403 | 0.83 | SIGMAR1 (0.38) | CYP1A2MAPK1PLA2G1BPLA2G2ACA12 | |
| Hydrochloric Acid SCHEMBL11597307 | 0.81 | CYP1A2 (0.43) | CYP1A2MAPK1PLA2G1BPLA2G2ACA12 | |
| SCHEMBL12225604 | 0.81 | PIK3CD (0.48) | CYP1A2MAPK1PLA2G1BPLA2G2ACA12 | |
| SCHEMBL13309417 | 0.81 | PLA2G1B (0.43) | CYP1A2MAPK1PLA2G1BPLA2G2ACA12 | |
| SCHEMBL7931178 | 0.81 | CYP1A2 (0.43) | CYP1A2MAPK1PLA2G1BPLA2G2ACA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120058084-A1 | Interferon Alpha Carrier Prodrugs | ASCENDIS PHARMA AS (DK) | 2012-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120058084-A1 | Interferon Alpha Carrier Prodrugs | IFNG, IFNAR1, IRF3 | CYP1A2 144/4885MAPK1 3981/4885PLA2G1B 1020/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.